Mycro 3|cas:944547-46-0|西域试剂

Mycro 3,99.21%

产品编号：Bellancom-100669| CAS NO：944547-46-0| 分子式：C₂₄H₁₇ClF₂N₆O₄| 分子量：526.88

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100669	￥1200.00	杭州北京（现货）
Bellancom-100669	￥1800.00	杭州北京（现货）
Bellancom-100669	￥2950.00	杭州北京（现货）
Bellancom-100669	￥6100.00	杭州北京（现货）
Bellancom-100669	￥11000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Mycro 3

产品介绍

Mycro 3 是一种具有口服活性的、有效的选择性 Myc-Max 二聚化抑制剂。Mycro 3 可用于胰腺癌的研究。

生物活性

Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc. Mycro 3 could be used for the research of pancreatic cancer.

体外研究

Mycro 3 is a potent and selective c-Myc inhibitor in whole cell assays, with weak inhibitory activity against Activator protein 1 (AP-1). Mycro 3 has a superior specificity profile to its predecessors. Mycro 3 inhibits the interaction between c-Myc and Max. Mycro 3 has high selectivity and inhibits c-Myc/Max dimerization and conjugation with DNA. Mycro 3 exhibits an excellent specificity with IC₅₀s of 0.25 and 9.0 µM for cells with intact Myc alleles and Myc-null cells, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Mycro 3 (100 mg/kg; oral administration; daily for two months) induces marked shrinkage of pancreatic ductal adenocarcinoma (PDA), increases cancer cell apoptosis, and reduces cell proliferation. Tumor growth is also drastically attenuated in Mycro 3-treated NOD/SCID mice carrying orthotopic or heterotopic xenografts of human pancreatic cancer cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Moribund Pdx1-cre/KRAS* mice bearing pancreatic ductal adenocarcinoma (PDA)
Dosage:	100 mg/kg
Administration:	Oral administration; daily for two months
Result:	Increased survival time. Mycro 3 administration was discontinued after two months, the mouse survived for an additional month.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Moribund Pdx1-cre/KRAS* mice bearing pancreatic ductal adenocarcinoma (PDA)
Dosage:	100 mg/kg
Administration:	Oral administration; daily for two months
Result:	Increased survival time. Mycro 3 administration was discontinued after two months, the mouse survived for an additional month.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (189.80 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8980 mL	9.4898 mL	18.9797 mL
5 mM	0.3796 mL	1.8980 mL	3.7959 mL
10 mM	0.1898 mL	0.9490 mL	1.8980 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: 2.5 mg/mL (4.74 mM); Clear solution; Need ultrasonic

此方案可获得 2.5 mg/mL (4.74 mM) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。